Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2026-04-14 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2025年度审计报告
Audit Report / Information Classification · 97% confidence The document is titled “2025年度审计报告” for 成都欧康医药股份有限公司 and contains the auditor’s opinion, basis of opinion, key audit matters, auditor responsibilities, and the detailed financial statements (balance sheet, income statement, cash flows, etc.) prepared in accordance with accounting standards. This clearly corresponds to a standalone audit report rather than an annual report or other filing. Therefore, it should be classified as an Audit Report (AR). FY 2025
2026-04-14 Chinese
2025年度募集资金存放、管理与实际使用情况的专项报告
Regulatory Filings Classification · 72% confidence The document is a detailed “special report on the deposit, management and actual use of raised funds” for 2025, required by the Beijing Stock Exchange/CSRC rules. It is not an initial fundraising announcement (which would be CAP), nor is it merely an announcement that a report is available (RPA). It is a mandated regulatory disclosure on proceeds usage that does not fit any of the other highly specific categories, so it falls into the fallback “Regulatory Filings” bucket.
2026-04-14 Chinese
2025年度独立董事述职报告（胥兴军）
Governance Information Classification · 75% confidence The document is a detailed annual performance report (‘述职报告’) by an independent director, describing governance activities, board and committee attendance, oversight of financial reporting and internal controls, and recommendations. It is not an annual financial report, earnings release, or announcement of a board change. Instead, it focuses on corporate governance practices and board oversight, fitting the Governance Information category.
2026-04-14 Chinese
关于拟减少注册资本暨修订《公司章程》的公告
Share Issue/Capital Change Classification · 85% confidence The document is a corporate announcement by 成都欧康医药股份有限公司 concerning the proposed repurchase and cancellation of restricted shares under its equity incentive plan, resulting in a reduction of registered capital and corresponding amendments to the Company’s Articles of Association. This is clearly an announcement of a capital structure change (reduction of registered capital and share count) rather than a full report or other filing type. Therefore it fits the Share Issue/Capital Change category (Code: SHA).
2026-04-14 Chinese
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 90% confidence The document is a special board report on the self-inspection of independent directors’ independence, detailing governance rules and compliance with listed company independent director regulations. It is not announcing management changes or reporting financial results, but rather disclosing governance practices and compliance procedures. This fits the definition of Governance Information (CGR).
2026-04-14 Chinese
关于使用闲置自有资金购买理财产品的公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement by the board of Chengdu O-Kang Pharmaceutical Co., Ltd. regarding the decision to use up to RMB 80 million of idle own funds to purchase wealth management products. This is not an earnings release, dividend notice, share issuance, merger activity, or management change. It describes a financial decision but not a capital raising or restructuring, and there is no regulatory form reference or shareholder vote results. It therefore does not neatly fit categories such as ER, DIV, SHA, POS, CAP, or MANG, making it a general regulatory announcement. The appropriate classification under the fallback regulatory category is RNS.
2026-04-14 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.